| Today's Edition
Monday May 9th, 2016
Stay ahead of the pack with "The QualityStocks Daily", our summary formatted newsletter
containing stock tips from hundreds of online investment newsletters.
Daily.QualityStocks.net
RenovaCare, Inc. (RCAR)
We are reporting on RenovaCare, Inc. (RCAR) today, here at the QualityStocks Daily Newsletter.
RenovaCare, Inc. is developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company’s initial product under development targets the body’s largest organ, the skin. RenovaCare is the developer of the patented CellMist™ and SkinGun™ technologies. These are for isolating and spraying a patient’s own stem cells onto burns and wounds for fast self-healing. RenovaCare is based in New York, New York.
RenovaCare’s flagship technology, the CellMist™ System, utilizes its patented SkinGun™ to spray a liquid suspension of a patient’s stem cells – the CellMist™ Solution – onto wounds. RenovaCare is developing its CellMist™ System as a promising new option for patients suffering from burns, chronic and acute wounds, as well as scars. The CellMist™ System targets an estimated 143 million patients globally who suffer burns, chronic and acute wounds, acne scarring, and skin defects and diseases such as vitiligo.
In investigative clinical use in the United States, SkinGun™ treatments have shown the potential to naturally and quickly heal burns and other serious wounds. Based on preliminary case studies, CellMist™ System patients can be treated within 90 minutes of entering an emergency room. A patient’s stem cells are isolated, processed, and sprayed onto wound sites for fast healing.
RenovaCare has a partnership to validate the science behind its innovative technology for treatments of wounds, burns and other skin defects. Its research partner is Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité - Universitätsmedizin Berlin, one of the world’s largest university hospitals.
The BCRT focuses on enhancing endogenous regeneration by cells, biomaterials, and factors that can be used to develop and implement ground-breaking therapies and products. Charité - Universitätsmedizin Berlin covers four campuses and consists of approximately 100 Departments and Institutes.
Recently, RenovaCare announced that it successfully completed the engineering, studies, and associated efforts required for submission of its foundational 510(k) filing to the U.S. Food and Drug Administration (FDA). RenovaCare’s planned submission will center on its liquid sprayer technology. The FDA’s clearance of a 510(k) submission allows for the marketing of a medical device in the United States.
Last week, RenovaCare announced favorable outcomes from laboratory studies conducted by Berlin-Brandenburg Center for Regenerative Therapies (BCRT). Charité scientists presented their findings from in vitro studies at the EPUAP Focus Meeting 2016 in Berlin, Germany. Data demonstrated that human skin stem cells sprayed with RenovaCare’s patented SkinGun™ device maintained 97.3 percent viability. Cell viability is vital to regenerating skin for burns, wounds, as well as cosmetic applications. Cell growth was comparable to pipetting, which is the industry’s broadly accepted ‘gold-standard’ for the deposition of cells.
RenovaCare, Inc. (RCAR), closed Monday's trading session at $2.05, up 0.99%, on 23,500 volume with 56 trades. The average volume for the last 60 days is 16,005 and the stock's 52-week low/high is $0.80/$2.85.
|
